Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03967379
Other study ID # 19-104
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 1, 2019
Est. completion date January 1, 2024

Study information

Verified date November 2023
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study is being done to evaluate whether the use of a mobile app can help transplant survivors experiencing sexual health problems.


Description:

Frequently survivors of stem cell transplantation report significant problems with their sexual function that impacts their quality of life, mood, and their intimacy and relationship with their partners. These issues can be very distressing to patients and their loved ones. The study doctors want to know if the use of a mobile app intervention focused on improving sexual function may improve participants overall care.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date January 1, 2024
Est. primary completion date January 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (=18 years) who underwent an autologous or allogeneic HCT at least 3 months prior to study enrollment. - Ability to speak English or able to complete questionnaires with assistance required from an interpreter or family member. - Positive screen for sexual dysfunction that is causing distress based on the NCCN survivorship guidelines Exclusion Criteria: - Recurrent disease requiring treatment - Significant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits the ability to participate in study procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mobile App + enhanced standard care
An intervention to help address sexual dysfunction among HCT survivors
Other:
Enhanced Standard Care
Standard of care administered by the institution

Locations

Country Name City State
United States Massachusetts General Hospital Cancer Center Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the feasibility of the intervention feasibility will be defined if at least 60% of eligible patients enroll and engage with at least 70% of the intervention modules 2 years
Secondary Compare patient-reported global satisfaction with sex (PROMIS Sexual Function and Satisfaction Measure) between the study groups patient-reported global satisfaction using the PROMIS Sexual Function and Satisfaction Measure. Higher scores indicate better global satisfaction with sex (there is a raw and T score. T score range 0-100) 8 and 12 weeks
Secondary Compare patient-reported interest in sexual activity (PROMIS Sexual Function and Satisfaction Measure - Interest in sexual activity domain) between the study groups compare patient-reported interest in sexual activity using the PROMIS Sexual Function and Satisfaction Measure - Interest in Sexual Activity Domain). higher score indicate better interest in sex (there is a raw and T score, T score range 0-100) 8 and 12 weeks
Secondary Compare patient-reported orgasm (PROMIS Sexual Function and Satisfaction Measure - Orgasm domain) between the study groups compare patient-reported orgasm using the PROMIS Sexual Function and Satisfaction Measure - Orgasm Domain). higher score indicate better orgasm (there is a raw and t-score, t-score range 0-100) 8 and 12 weeks
Secondary For males: compare patient-reported erectile function (PROMIS Sexual Function and Satisfaction Measure - Erectile function domain) between the study groups for males: compare patient-reported erectile function using the PROMIS Sexual Function and Satisfaction Measure - Erectile Function Domain). higher score indicate better erectile function (there is a raw and t-score, T-score range 0-100) 8 and 12 weeks
Secondary For females: compare patient-reported lubrication and vaginal comfort (PROMIS Sexual Function and Satisfaction Measure - lubrication and vaginal comfort domains) between the study groups For females: compare patient-reported vaginal comfort and lubrication using the PROMIS Sexual Function and Satisfaction Measure- Lubrication and Vaginal Comfort Domain). higher score indicate better lubrication and vagina comfort (there is a raw and T-score, T-score range 0-100) 8 and 12 weeks
Secondary Compare patient reported quality of life (FACT-BMT) between the study groups compare patient-reported quality of life using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). higher score indicate better quality of life (range 0-196) 8 and 12 weeks
Secondary Compare patient reported depression symptoms (HADS-depression) between the two study groups compare patient-reported depression symptoms using Hospital Anxiety and Depression Scale (HADS-Depression). higher subscale score indicate worse depression symptoms (range 0-21) 8 and 12 weeks
Secondary Compare patient reported anxiety symptoms (HADS-anxiety) between the two study groups compare patient-reported depression symptoms using Hospital Anxiety and Depression Scale (HADS-Anxiety). higher subscale score indicate worse anxiety symptoms (range 0-21) 8 and 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04340024 - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Active, not recruiting NCT03609177 - Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly N/A
Active, not recruiting NCT04591431 - The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Phase 2
Recruiting NCT06103669 - Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) N/A
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Completed NCT03736746 - Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals N/A
Completed NCT03638453 - Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention N/A
Recruiting NCT06397651 - A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live 1:1 Exercise Coaching and Personalised Digital Application on Cancer Survivors' Cost of Care N/A
Active, not recruiting NCT03850912 - Symptom Management Implementation of Patient Reported Outcomes in Oncology N/A
Completed NCT03392090 - SHARE (Sharing Goals and Preferences) Study N/A
Completed NCT03244826 - Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation N/A
Recruiting NCT03517332 - Circulating Tumor DNA Exposure in Peripheral Blood
Completed NCT03721926 - A Geriatric Oncology Collaborative Care Intervention for Older Adults With Advanced Cancer N/A
Completed NCT05176860 - Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy N/A
Active, not recruiting NCT03674047 - Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) Phase 2
Active, not recruiting NCT03752268 - Development of an Intervention to Enhance Cancer Pain Management N/A